Fig. 6From: Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patientsPrincipal Component Analysis (PCA) of differentially expressed proteins. PCA plots of the (a) 178 differentially expressed protein in EDT plasma samples and (b) 32 differentially expressed proteins altered in response to immunotherapy showed good separation between the responding (blue) and non-responding (red) patientsBack to article page